文献速递造血干细胞移植与细胞治疗

美国商业保险参保者中异基因造血干细胞移植后非感染性肺部并发症与闭塞性细支气管炎综合征的经济负担

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States.
PubMed 文献 · Blood Adv · 2022-01-01

该纵向回顾性研究利用IQVIA PharMetrics Plus商业理赔数据,纳入2006年1月1日至2018年9月30日期间接受异基因造血干细胞移植的0至64岁患者,量化非感染性肺部并发症(NIPC)及闭塞性细支气管炎综合征(BOS)的经济负担。2162例移植患者中254例发生NIPC,155例经倾向性评分匹配与非NIPC患者比较;移植后第一年NIPC患者住院率更高(3.8±3.2 vs 2.6±2.4,P<.001),总费用更高(567 870美元 vs 412 400美元,P=.07)。

要点

  • 移植后第一年NIPC患者住院率显著高于非NIPC患者(3.8±3.2 vs 2.6±2.4,P<.001)。
  • 移植后第一年NIPC患者总费用567 870美元,非NIPC患者412 400美元(P=.07)。
  • 可观察多年者中NIPC患者费用持续更高,移植后前3年住院率显著更高。

核心结论

  • 发生NIPC的异基因造血干细胞移植患者较未发生NIPC者医疗资源利用更高、费用更高。

研究设计与样本

  • 纵向回顾性研究,使用IQVIA PharMetrics Plus数据库的商业理赔数据。
  • 研究对象为2006年1月1日至2018年9月30日期间接受异基因造血干细胞移植的0至64岁患者,移植前可观察12个月、移植后最多观察5年。
  • 2162例异基因造血干细胞移植患者中254例发生NIPC,其中155例经倾向性评分匹配与非NIPC患者比较。

主要发现

  • 移植后第一年NIPC患者住院率3.8±3.2,非NIPC患者2.6±2.4(P<.001)。
  • 移植后第一年NIPC患者总费用567 870美元,非NIPC患者412 400美元(P=.07)。
  • 移植后第一年NIPC患者住院费用452 475美元,非NIPC患者300 202美元(P=.06)。
  • 在可观察更多年份的患者中,NIPC患者费用持续更高,反映移植后前3年住院率显著更高。
  • 对诊断可能反映BOS的患者的亚组分析结果与上述发现一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Noninfectious pulmonary complications (NIPC) after allogeneic hematopoietic stem cell transplantation (alloHSCT), including bronchiolitis obliterans syndrome (BOS), cause significant morbidity and mortality, but their impact on health care resource utilization (HRU) and costs is unknown. This longitudinal retrospective study quantified the economic burden of NIPC and BOS in alloHSCT patients using commercial claims data from the IQVIA PharMetrics Plus database. Study patients were aged 0 to 64 years and underwent alloHSCT between 1 January 2006 and 30 September 2018, and were observable 12 months before and up to 5 years after index alloHSCT. NIPC patients were identified using International Classification of Disease (ICD) diagnosis codes. Outcomes were mean per patient HRU (inpatient admissions, outpatient office, hospital visits, and prescription medications) and costs paid by insurers in each post-transplant year. Among 2162 alloHSCT patients, 254 developed NIPCs, and 155 were propensity score (PS)-matched to non-NIPC patients. The year following transplantation, NIPC patients had significantly higher inpatient admission rates (3.8 ± 3.2 vs non-NIPC: 2.6 ± 2.4; P < .001) and higher total costs ($567 870 vs $412 400; P = .07), reflecting higher costs for inpatient admissions ($452 475 vs $300 202; P = .06). Among those observable for more years, costs remained higher for NIPC patients, reflecting significantly higher inpatient admission rates in the first 3 years following transplant. Subanalysis of patients with diagnoses likely reflective of BOS were consistent with these findings. AlloHSCT patients who developed NIPC had higher health care resource utilization and incurred higher costs compared with alloHSCT patients who did not develop NIPC following transplant.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sacks NC, Healey BE, Raza S, et al. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv. 2022. PMID: 34807973. doi:10.1182/bloodadvances.2021004364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。